Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro) is indicated for use as monotherapy in the treatment of early-stage Parkinson's disease or, in the EU, as an adjunct to levodopa across all disease stages. Transdermal rotigotine is an effective and generally well tolerated addition to the armamentarium for the control of Parkinson's disease, with the once-daily transdermal patch system offering several practical advantages and the possible benefits of avoiding pulsatile dopaminergic stimulation. Transdermal rotigotine was superior to placebo in patients with early-stage and advanced Parkinson's disease, although noninferiority to the oral dopamine agonists ropinirole or pramipexole was not consistently demonstrated. Additional active comparator trials would be of interest. In the meantime, transdermal rotigotine offers a convenient new treatment option for patients with Parkinson's disease.
Baldwin
Claudine M
CM
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@dis.co.nz
Keating
Gillian M
GM
D000279:Administration, Cutaneous; D019992:Databases as Topic / Q000706:statistics & numerical data; D018491:Dopamine Agonists / Q000008:administration & dosage*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D012189:Retrospective Studies; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*
D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine